Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
LIU Yun-Chao1,2, ZHANG Ying2, QIN Shu-Cun1,3,4, XUE Jun-Li1,3,4,*
1Central Laboratory of the Second Affiliated Hospital, Shandong First Medical University, Taian 271000, China；2College of Pharmacy, Shandong First Medical University, Taian 271000, China；3Laboratory of Major Diseases and Hydrogen Medical Translational Applications in Universities of Shandong Province, Taian 271000, China；4Key Laboratory of Hydrogen Biomedical Research of Health Commission of Shandong Province, Taian 271000, China
Metabolic associated fatty liver disease (MAFLD) is a liver disease with hepatocyte steatosis caused by metabolic disorders, which is closely related to obesity, diabetes, metabolic dysfunction, and other factors. Its pathological process changes from simple steatosis, liver inflammation to non-alcoholic steatohepatitis (NASH), and then leads to liver fibrosis, cirrhosis, and liver cancer. At present, no specific therapeutics are available for treatment of MAFLD targeting its etiology. Celastrol is the main active component of the traditional Chinese medicine Celastrus orbiculatus Thunb. In recent years, it has been found that celastrol shows important medicinal value in regulating lipid metabolism, reducing fat and weight, and protecting liver, and then ameliorates MAFLD. This article reviews the related research progress of celastrol in the prevention and treatment of MAFLD, so as to provide a reference for the comprehensive development and utilization of celastrol.
Corresponding author: XUE Jun-Li E-mail: firstname.lastname@example.org, email@example.com, firstname.lastname@example.org
Citing This Article：
LIU Yun-Chao, ZHANG Ying, QIN Shu-Cun, XUE Jun-Li. Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease. Acta Physiol Sin 2023; 75 (5): 682-690 (in Chinese with English abstract).